story of the week
Sorafenib Maintenance After Allo-HSCT for AML With FLT3-Internal Tandem Duplication Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
J. Clin. Oncol 2020 Jul 16;[EPub Ahead of Print], A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, R Wäsch, M Bornhäuser, T Berg, F Lang, G Ehninger, H Serve, R Zeiser, EM Wagner, N Kröger, C Wolschke, M Schleuning, KS Götze, C Schmid, M Crysandt, E Eßeling, D Wolf, Y Wang, A Böhm, C Thiede, T Haferlach, C Michel, W Bethge, T Wündisch, C Brandts, S Harnisch, M Wittenberg, HG Hoeffkes, S Rospleszcz, A Burchardt, A Neubauer, M Brugger, K Strauch, C Schade-Brittinger, SK MetzelderFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.